Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib
Background. Antithrombotic therapy in chronic lymphocytic leukemia (CLL) patients is challenging, as this category of patients is initially characterized by high risk of hemorrhagic complications. The use of ibrutinib influencing the platelet function constitutes an additional bleeding risk. A cruci...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
Practical Medicine Publishing House
2019-10-01
|
| Seri Bilgileri: | Клиническая онкогематология |
| Konular: | |
| Online Erişim: | https://bloodjournal.ru/index.php/coh/article/view/342 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|